Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

2.

Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.

D'Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, Rose-Zerilli M, Strefford J, Plass C, Johnson PW, Steele AJ, Packham G, Stevenson FK, Oakes CC, Forconi F.

Blood. 2016 Aug 11;128(6):816-26. doi: 10.1182/blood-2016-03-707786. Epub 2016 Jun 14.

3.

Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.

Tracy I, Tapper W, Parker A, Gardiner A, Sadullah S, Pratt G, Copplestone A, Oscier D, Best OG.

Br J Haematol. 2017 Sep;178(5):824-826. doi: 10.1111/bjh.14172. Epub 2016 Jun 13. No abstract available.

PMID:
27292869
4.

The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors.

Malcikova J, Stalika E, Davis Z, Plevova K, Trbusek M, Mansouri L, Scarfò L, Baliakas P, Gardiner A, Sutton LA, Francova HS, Agathangelidis A, Anagnostopoulos A, Tracy I, Makris A, Smardova J, Ghia P, Belessi C, Gonzalez D, Rosenquist R, Oscier D, Pospisilova S, Stamatopoulos K.

Br J Haematol. 2014 Aug;166(4):621-5. doi: 10.1111/bjh.12893. Epub 2014 Apr 12. No abstract available.

PMID:
24725250
5.

Defining the prognosis of early stage chronic lymphocytic leukaemia patients.

Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C.

Br J Haematol. 2012 Feb;156(4):499-507. doi: 10.1111/j.1365-2141.2011.08974.x. Epub 2011 Dec 15.

PMID:
22171799
6.

A new minimal deleted region at 11q22.3 reveals the importance of interpretation of diminished FISH signals and the choice of probe for ATM deletion screening in chronic lymphocytic leukemia.

Gardiner A, Parker H, Glide S, Mould S, Robinson H, Tracy I, Stankovic T, Oscier D, Strefford J.

Leuk Res. 2012 Mar;36(3):307-10. doi: 10.1016/j.leukres.2011.08.002. Epub 2011 Sep 28.

PMID:
21955805
7.

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.

Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S; European Research Initiative on CLL (ERIC).

Leukemia. 2010 Dec;24(12):2072-9. doi: 10.1038/leu.2010.208. Epub 2010 Sep 23.

PMID:
20861914
8.

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease.

Best OG, Gardiner AC, Davis ZA, Tracy I, Ibbotson RE, Majid A, Dyer MJ, Oscier DG.

Leukemia. 2009 Jan;23(1):212-4. doi: 10.1038/leu.2008.260. Epub 2008 Sep 25. No abstract available.

PMID:
18818700
9.

Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.

Alarcón GS, Tracy IC, Strand GM, Singh K, Macaluso M.

Ann Rheum Dis. 1995 Sep;54(9):708-12.

10.

Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?

Bridges SL Jr, López-Méndez A, Han KH, Tracy IC, Alarcón GS.

J Rheumatol. 1991 Jul;18(7):984-8.

PMID:
1920333
11.

Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. A survey of Alabama rheumatologists.

Baum SK, Tracy IC, Henderson EH, Alarcón GS.

Arthritis Care Res. 1991 Mar;4(1):48-51.

PMID:
11188587
12.

Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment.

Alarcón GS, Tracy IC, Blackburn WD Jr.

Arthritis Rheum. 1989 Jun;32(6):671-6.

PMID:
2735960

Supplemental Content

Support Center